|
|
C3 adjuvant |
|
Vaxjo ID |
373 |
|
Vaccine Adjuvant Name |
C3 adjuvant |
|
Adjuvant VO ID |
VO_0005536
|
|
Description |
molecular adjuvant that induces Th2 response |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
fragment of the third complement protein, C3 in the complement pathway |
|
Function |
B cell activation and increased antigen presentation on APCs |
| References |
Dempsey et al., 1996: Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science (New York, N.Y.). 1996; 271(5247); 348-350. [PubMed: 8553069].
Ross et al., 2001: Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS research and human retroviruses. 2001; 17(9); 829-835. [PubMed: 11429124].
Yu et al., 2006: Yu M, Li DJ, Wang XL, Yuan MM, Zhu Y, Yao XY, Li HP. [Molecular adjuvant C3d up-regulates both B7-1 and B7-2 expression on Raji cells]. Fen zi xi bao sheng wu xue bao = Journal of molecular cell biology. 2006; 39(1); 77-82. [PubMed: 16944576].
|
|
